AstraZeneca PLC (OTCMKTS:AZNCF) is seeing a significant decrease in short interest

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report ) was the target of a significant drop in short interest in August. As of August 15th, there was short interest totaling 9,200 shares, a decrease of 20.7% from July 31st’s total of 11,600 shares. Based on an average daily volume of 2,100 shares, the short interest rate is currently 4.4 days.

AstraZeneca price performance

Shares of AZNCF stock opened at $172.02 on Friday. The stock’s fifty day simple moving average is $159.68 and the two hundred day simple moving average is $148.18. AstraZeneca has a 1 year low of $118.16 and a 1 year high of $174.97.

AstraZeneca cuts dividend

The company also recently announced a dividend, which will be paid on Monday, September 9th. Stockholders of record on Friday, August 9th will be given a $1.00 dividend. The ex-dividend date of this dividend is Wednesday, August 7. AstraZeneca’s payout ratio is currently 343.14%.

AstraZeneca Institutional Trading

An institutional investor recently bought a new position in shares of AstraZeneca. Kennedy Capital Management LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, according to its most recent filing with the SEC. The fund acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. Institutional investors own 40.87% of the company’s shares.

About AstraZeneca

(Get a free report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbilocort, Teztri Saspireph, , Pulmicort, Bevespi and Daliresp for cardiovascular, renal, metabolism and oncology.

Read more

Get news and reviews for AstraZeneca Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca and related companies with MarketBeat.com’s FREE daily email newsletter.